

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for modulating an immune response in an animal, comprising administering a compound which binds to ~~a C-type lectin~~ a protein with the amino acid sequence of SEQ ID NO: 2 (DC-SIGN) on the surface of a dendritic cell, ~~with the proviso that the C-type lectin is not the DEC-205 receptor.~~
2. (original) The method of claim 1 wherein said modulating is a reducing of the immune response.
3. (original) The method of claim 1 wherein said animal is a mammal.
4. (original) The method of claim 3 wherein said mammal is a human.
5. (original) The method of claim 1 wherein said compound reduces one or more interactions between a dendritic cell and a T cell.
6. (currently amended) The method of claim 1 wherein said compound reduces adhesion between ~~said C-type lectin~~ DC-SIGN and an ICAM receptor on the surface of a T cell.
7. (original) The method of claim 6 wherein said ICAM receptor is selected from the group consisting of ICAM-2 receptors and ICAM-3 receptors.
8. (original) The method of claim 1 wherein said method i) induces tolerance, ii) is immunotherapeutic, iii) induces immunosuppression, iv) treats an autoimmune disease, or v) treats an allergy.

9. (currently amended) The method of claim 1 wherein said compound is selected from the group consisting of a mannose carbohydrate, a fucose carbohydrate, ~~a plant lectin~~, an antibiotic, a sugar, a protein, and an antibody.

10. (withdrawn) The method of claim 9 wherein said mannose carbohydrate is mannan or D-mannose.

11. (withdrawn) The method of claim 9 wherein said fucose carbohydrate is L-fucose.

12. (withdrawn) The method of claim 9 wherein said plant lectin is concanavalin A.

13. (withdrawn) The method of claim 9 wherein said antibiotic is pradimicin A.

14. (withdrawn) The method of claim 9 wherein said sugar is selected from the group consisting of N-acetyl-D-glucosamine and galactose.

15. (withdrawn) The method of claim 9 wherein said protein is selected from the group consisting of gp120, analogs of gp120 and fragments of gp120.

Claims 16 - 18. (canceled)

19. (original) The method of claim 9 wherein said antibody is a monoclonal antibody.

Claims 20 - 22. (canceled)

23. (currently amended) The method of claim 9 wherein said antibody is selected from the group consisting of ~~AZN-D1 and AZN-D2~~ i) an antibody produced by hybridoma ECACC accession number 99040818 and ii) an antibody produced by hybridoma ECACC accession number 99040819.